GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022
March 21 2022 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, announced today that its Chief Scientific
Officer, Mark J. Newman, Ph.D., will deliver a presentation titled,
“Design of a Universal SARS-CoV-2 Vaccine Effective Against
Evolving Variants” during the Vaccine Summit Boston being held
virtually on March 28-31, 2022.
In his talk, Dr. Newman will discuss GeoVax’s vaccine design
strategy for developing a universal SARS-CoV-2 vaccine and present
efficacy and immunogenicity data for the Company’s lead universal
vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane
(M) and Envelope (E) proteins, providing a targeting of both
antibody and cellular (T-cell) immune responses. This novel,
multi-antigen approach is designed to potentially provide a more
robust and durable protection, encompassing variants before they
emerge versus “chasing the variants” as appears the case with the
current authorized vaccines.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines and immunotherapies against infectious
diseases and cancer using novel proprietary platforms. GeoVax’s
product pipeline includes two ongoing Phase 2 clinical trials of
GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster
vaccine to mRNA vaccines authorized by the U.S. Food and Drug
Administration (FDA) and as a primary vaccine for use in
immunocompromised patients. In addition to GEO-CM04S1 for COVID-19,
GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The
Company is also conducting a Phase 1/2 clinical trial of Gedeptin®
for treatment of head and neck cancer. Gedeptin® has been granted
orphan drug status by the FDA. Additional research and development
programs include preventive vaccines against Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and
malaria, as well as immunotherapies for multiple solid tumors. The
Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our website:
www.geovax.com.
Contact:GeoVax Labs,
Inc.investor@geovax.com 678-384-7220
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2024 to Oct 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Oct 2023 to Oct 2024